liso-cel (formerly JCAR017), and it owns nearly 10% of Juno Therapeutics' stock, yet that may not be enough to satisfy Celgene's desire to become a gene-therapy leader. According to The Wall Street Journal, Celgene is thinking about …
Cel-Sci - entered definitive agreement with one institutional investor for offering of shares of stock with proceeds of about $1.51 million in direct offering * Cel-Sci corp- intends to use net proceeds from offering for phase 3 clinical study and …
Reuters12mon
CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder’s Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common stock. CEL-SCI expects the split to be …
You can’t win with the tabloids. You’re either too fat, too thin, or hiding a deadly secret. This week’s tabloids continue their obsession with the stars’ weight, led by the ‘National Enquirer’ and its team of reporters expertly trained by ...
* Cel-Sci Corp - a 1-for-25 reverse split was authorized for its outstanding shares of common stock Source text for Eikon: Further company coverage:
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CVM at https://www.zacks.com/ap/CVM Keywords: Cel-Sci, Earnings Report